In sub-study A, 126 patients with 25% or higher percentage of PD-L1 expressing tumor cells (TC) were randomly allocated (1:1) to receive either durvalumab or chemotherapy (gemcitabine and vinorelbine or erlotinib), whereas in sub-study B, 469 patients with PD-L1 expressing TC lower than 25% were randomly allocated (3:2:2:1) to receive either durvalumab plus tremelimumab, chemotherapy, durvalumab alone, or tremelimumab alone. The gene discussed is CD274; the disease is neoplasm.